Fig. 2

Correlation between LGALS3 gene expression and survival prognosis of various human cancers. (A) We used GEPIA2 to obtain the OS analyses of LGALS3 across the 23 types of cancer. The survival map and Kaplan-Meier curves with positive results are offered. (B) The prognostic value of LGALS3 in HCC was assessed according to DSS by Kaplan–Meier plotter. (C) Representative immunofluorescence images of LGALS3 protein in HCC tissues and adjacent normal tissues. Scale bar, 50 μm. Immunofluorescence image quantification results (right). (D) qRT-PCR analysis of LGALS3 expression in tumor and adjacent normal tissues from 5 HCC patients. (E) The differential expression of LGALS3 in HCC with main pathological stages (stage I, stage II, stage III, and stage IV) assessed by GEPIA2. (F) The expression distribution of LGALS3 in normal tissues and HCC with various tumor grades. (G) ROC curve for LGALS3 in predicting 1-, 3-, and 5-year OS. (H) ROC curve for LGALS3 in predicting 1-, 3-, and 5-year DSS. The higher values of AUC corresponding to higher predictive power. *p value < 0.05; ***p value < 0.001